Health Care·Life Sciences Tools & Services·$9.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.98 | N/A | +4.03% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.98 | N/A | +4.03% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting a commitment to long-term growth. They chose not to provide specific guidance for the upcoming quarters.
We are pleased with our EPS performance this quarter.
While we did not provide guidance, we remain focused on our long-term strategy.
Revvity's strong EPS performance indicates effective cost management and profitability, which likely contributed to the stock's 3.46% increase. However, the lack of revenue data and guidance leaves some uncertainty for investors. Overall, the positive EPS surprise may bolster investor confidence in the company's direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
EXXON MOBIL CORP
Apr 26, 2024